1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0 
Protocol  #BL0319 29 October 2019 
Clinical Evaluation of the Safety and Efficacy  of a 
1064 nm Diode Laser , Pulsed ElectroMagnetic Fields  
and Vac uum Assisted Multipolar Radio Frequency for 
Non-invasive Fat Reduction of the Abdomen and 
Flanks  
Protocol Identifying Number: BL0319 
Funded by : Venus Concept  Ltd. 
Version Number: v 5 .0 
29 October 2019 
 
 
    
 
   
Sponsor Contact  
 
 
VP QA RA and Clinical Affairs 
Address: Venus Concept Ltd.  
235 Yorkland Blvd Suite 900  
Toronto, Ontari o   M2J 4Y8  
Canada  
Telephone 888 -907-0115  
 
 
 
 
            _______________________________ _  ____________________  
             Signature of Sponsor Representative                       Date: (DD/MM/YYYY  

ii 
 Table of Contents  
LIST OF ABBREVIATIONS  ....................................................................................................................................... 1  
STATEMENT OF COMPLIANCE  ............................................................................................................................. 2  
PROTOCOL SUMMARY  ........................................................................................................................................... 3  
SCHEMATIC OF STUDY DESIGN  .......................................................................................................................... 1  
1 KEY ROLES .................................................................................................................................................... 1  
2  INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE ........................ 1  
2.1 Background Information  ...................................................................................................................... 1  
2.2 Rationale  ............................................................................................................................................... 2  
2.3 Potential Risks and Benefits  ..............................................................................................................  2 
2.3.1  Known Potential Risks  ..................................................................................................... 2  
2.3.2  Known Potential Benefits  ................................................................................................ 3  
3 OBJECTIVES AND PURPOSE .................................................................................................................... 3  
4 STUDY DESIGN  AND ENDPOINTS  ........................................................................................................... 3  
4.1 Description of the Study Design  ........................................................................................................ 3  
4.2.1  Primary EndpointS  ........................................................................................................... 4  
4.2.2  Secondary Endpoints  ...................................................................................................... 4  
5 STUDY ENROLLMENT AND WITHDRAWAL  ........................................................................................... 4  
5.1 Participant Inclusion Criteria ..............................................................................................................  4 
5.2 Participant Exclusion Criteria  ............................................................................................................. 4  
5.3 Strategies for Recruitment and Retention ........................................................................................ 5  
5.4 Participant Withdrawal or termination  ............................................................................................... 5  
5.4.1  Reasons for Withdrawal or Termination  ....................................................................... 5  
5.4.2  Handling of Participant Withdrawals or termination  .................................................... 6  
5.5 Premature Termination or Suspension of Study ............................................................................. 6  
6 STUDY device  ................................................................................................................................................ 7  
6.1 Study device and Control Description  .............................................................................................. 7  
6.1.1  Acquisition  ......................................................................................................................... 7  
6.1.2  Device Specific Considerations  ..................................................................................... 7  
6.2 Study device Accountability Procedures  .......................................................................................... 7  
7 STUDY PROCEDURES AND SCHEDULE  ................................................................................................ 8  
7.1 Study Procedures/Evaluations  ........................................................................................................... 8  
7.1.1  Study specific procedures  ............................................................................................... 8  
7.2 Labo ratory Procedures/Evaluations  .................................................................................................. 8  
7.2.1  Clinical Laboratory Evaluations  ................................................................ ......................  8 
7.3 Study Schedule  .................................................................................................................................... 8  
7.3.1  Screening .......................................................................................................................... 8  
7.3.2  Enrollment/Baseline  ......................................................................................................... 9  
7.3.3  FOLLOW UP and Final Study Visit  ............................................................................. 11 
7.3.4  Early Termination Visit  .................................................................................................. 11 
7.3.5  UNSCHEDULED Visit  ................................................................................................... 11 
7.4 Concomitant Medications, Treatments, and Procedures  .............................................................  12 
7.5 Prohibited Medications, Treatments, and Procedures  ................................................................. 12 
7.6 Rescue Medications, Treatments, and Procedures  ..................................................................... 12 
8 ASSESSMENT OF SAFETY ...................................................................................................................... 12 
8.1 Specification of Safety Parameters  ................................................................................................. 12 
iii 
 8.1.1  Definition of Adverse Events (AE)  ............................................................................... 13 
8.1.2  Definition of Serious Adverse Events (SAE) .............................................................. 13 
8.1.3  Definition of Unanticipated Problems (UP) ................................................................. 13 
8.2 Classification of an Adverse Event .................................................................................................. 13 
8.2.1  Severity of Event  ............................................................................................................ 13 
8.2.2  Relationship to Study Agent  ......................................................................................... 14 
8.2.3 Expectedness  ................................................................................................................. 14 
8.3 Time Period and Frequency for Event Assessment and Follow -Up .......................................... 14 
8.4 Reporting Procedures  ....................................................................................................................... 15 
8.4.1  Adverse Event Reporting  .............................................................................................. 15 
8.4.2  Serious Adverse Event Reporting  ............................................................................... 15 
8.4.3  Unanticipated Problem Reporting  ................................................................................ 15 
8.4.4  Reporting of Pregnancy  ................................................................................................ 16 
8.5 Study Halting Rules  ........................................................................................................................... 16 
8.6 Safety Oversight  ................................................................................................................................ 16 
9 CLINICAL MONI TORING  ............................................................................................................................ 16 
10 STATISTICAL CONSIDERATIONS  .......................................................................................................... 17 
10.1 Statistical and Analytical Plans  ........................................................................................................ 17 
10.2 Analysis Datasets  .............................................................................................................................. 17 
10.3 Description of Statistical Methods  ................................................................................................... 17 
10.4.1  General Approach  .......................................................................................................... 17 
10.4.2 Analysis of the primary endpoints  ...................................................................................................... 18 
10.4.3  Analysis of the secondary endpoints  ........................................................................... 19 
10.4.5  Safety analysis  ............................................................................................................... 19 
10.4.6  Adherence and Retention Analyses  ............................................................................ 20 
10.4.7  Baseline Descriptive Statistics  .....................................................................................  20 
10.4.8  Planned Interim Analyses  ............................................................................................. 20 
10.4.10  Tabulation of Individual Response Data  ..................................................................... 20 
10.4.11  Exploratory Analyses  ..................................................................................................... 20 
10.5 Sample Size  ....................................................................................................................................... 20 
10.6.1  Enrollment/ Randomization/ Masking Procedures  .................................................... 21 
10.6.2  Evaluation of Success of Blinding  ............................................................................... 21 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  ................................... 21 
12 QUALITY ASSURANCE AND QUALITY CONTROL  ...................................... ........................................ 21 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  ................................................................................... 22 
13.1 Ethical Standard  ................................................................................................................................. 22 
13.2 Institutional Review Board  ................................................................................................................ 22 
13.3 Informed Consent Process  ............................................................................................................... 22 
13.3.1  Consent/assent and Other Informational Documents Provided to Participants  .... 22 
13.3.2  Consent Procedures and Documentation  .................................................................. 23 
13.4 Participant and data Confidentiality  ................................................................................................ 23 
13.4.1  Research Use of Stored Human SAMPLES, SPECIMENS or Data ...................... 23 
14 DATA HANDLING AND RECORD KEEPING  .......................................................................................... 23 
14.1 Data Collection and Management Responsibilities  ...................................................................... 24 
14.2 Study Records Retention  .................................................................................................................. 24 
14.3 Protocol Deviations  ............................................................................................................................ 24 
iv 
 14.4 Publicati on and Data Sharing Policy  ............................................................................................... 25 
15 STUDY ADMINISTRATION  ........................................................................................................................ 25 
15.1 Study Leadership  ............................................................................................................................... 25 
16 CONFLICT OF INTEREST POLICY  .......................................................................................................... 25 
17  LITERATURE REFERENCES.................................................................................................................... 25 
APPENDIX ................................................................................................................................................................. 26 
 
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0 
Protocol  #BL0319 29 October 2019 
LIST OF ABBREVIATIONS  
 
 
AE 
ANCOVA  
BMI 
CFR 
CRF 
CW 
FDA 
GCP 
GUI 
ICH 
ICH E6 
 
ICMJE  
IRB 
ISO 14155:2011  
MedDRA  
PI 
QC 
SAE 
SAP 
SC 
SLIQ  
US 
UP 
 Adverse Event  
Analysis of Covariance  
Body Mass Index  
Code of Federal Regulations  
Case Report Form  
Continuous Wave  
Food and Drug Administration  
Good Clinical Practice  
Graphical User Interface  
International Conference on Harmonisation  
International Conference on Harmonisation Guidance for Industry, Good Clinical  
Practice: Consolidated Guidance  
International Committee of Medical Journal Editors  
Institutional  Review Board  
International Organization for Standardization Good Clinical Practices for Clinical  
Medical Dictionary for Regulatory Activities  
Principal Investigator  
Quality Control  
Serious Adverse Event  
Statistical Analysis Plan  
Subcutaneous  
Simple Lifestyle Indicator Questionnaire  
Ultrasound  
Unanticipated Problem  
 
 
  
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 2 of 3 
 STATEMENT OF COMPLIANCE  
 
The trial will be carried out in accordance with Good Clinical Practice (GCP) as required by the following :  
• United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 
46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812) or equivalent local regulatory regulations or guidelines  
• ICH E6  
• ISO 14155:2011  
 All key personnel (all individuals responsible for the design and conduct of this trial) have completed Human Subjects Protection Training.  
 
I agree to ensure that all staff members involved in the conduct of this study are informed about their 
obligations in meeting the above commitments.  
Principal Investigator: ________________________________ 
Print/Type Name  
Signed: _____________________________________ Signature    Date: ______________  
  
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 3 of 3 
 PROTOCOL SUMMARY  
 
TITLE  Clinical Evaluation of the Safety and Efficacy of a 1064 nm Diode Laser , Pulsed 
ElectroMagentic Fields  and vaccum assisted radio frequency for Non-Invasive 
Fat Reduction of the Abdomen and Flanks   
SUMMARY  Open-label, baseline -controlled,  multi-center  study evaluating a  1064  nm diode 
laser , pulsed electromagnetic fields  and vaccum assisted radio frequency for 
non-invasive fat reduction  of the abdomen and f lanks . The s tudy will enroll up 
to 200 subjects  requesting non -invasive lipolysis of the abdomen and flanks .  
Each s ubject will receive 3 study  treatments of the diode laser and 3 treatments 
of the pulsed electromagnetic fields and vaccum  assisted radio frequency study 
treatments .  Subjects will be followed at 16 and 24 weeks post  diode 
treatments .  Sixteen week and 24 week post treatment outcome  will be 
compared to baseline.  
OBJECTIVE  The objective of this clinical study is to assess the  safety and efficacy of using a 
1064  nm diode laser for non -invasive fat reduction of the abdomen and flanks . 
ENDPOINT  Primary endpoints  
• Photographic evaluation by an independent, blinded reviewer with 
correct identification of pre -treatment baseline images when compared 
to post -treatment images taken at sixteen and 24 weeks   
Secondary endpoints  
• To assess subject satisfaction with 16 and 24 weeks  using the 5 -Point 
Likert Subject Satisfaction Scale  and subject questionnaire  
Safety 
• Subject’s assessment of dis comfort and pain  post -treatment as 
measured by the Wong -Baker Faces Pain rating scale  
• Subjects experiencing a treatment -related adverse event ( AE) 
POPULATION  The study will enroll up to  200 male and female subjects , ≥ 18 years of age who 
are seeking fat reduction  of the flanks  and abdomen    
PHASE  Post -Market  
NUMBER OF SITES  Up to 20 sites   
DESCRIPTION OF 
DEVICE  The investigational device (Venus Bliss ™) is a non -invasive medical aesthetic 
device designed for body contouring.  The device is comprised of a console, four 
1064 nm (± 10 nm)  diode laser applicators (60 mm x 60 mm).   A belt is included 
to allow the operator to secure the laser applicators on the lipolysis treatment 
area, allowing hands free operation. The device uses vaccum assisted 
radiofrequency (RF) and PEMF (pulsed electromagnetic field) technology  which 
has been shown in clinical studies to be safe and effective in body  
circumferential reduction  and skin tightening .   
STUDY DURATION  Two years   
PARTICIPANT 
DURATION  24 weeks  
 
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0 
Protocol  #BL0319 29 October 2019 
 
SCHEMATIC OF STUDY DESIGN  
Visit  Week  Event  
Screening  0 Obtain informed consent, physicial exam, medical history, concomitant medication, 
screen potential subjects by inclusion and exclusion criteria  
1 1 Urine pregnancy test, AE's, concomitant medication, baseline photographs , 
optional ultrasound imaging  
1 1 Diode and RF study tx, pain response  
2 8 Photos, optional ultrasound imaging, Diode and RF study tx, pain response, 
satisfaction questionnaire  
3 16 Photos, optional ultrasound imaging, Diode and RF study tx pain response, 
satisfaction questionnaire  
4 24 optional ultrasound imaging  , Follow up, photography, satisfaction questionnaire 
17 KEY ROLES  
 
 
VP QA RA and Clinical Affairs 
Address: Venus Concept Ltd.  
235 Yorkland Blvd Suite 900  
Toronto, Ontari o   M2J 4Y8  
Canada  Telephone 888 -907-0115  
 
2  INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  
2.1 BACKGROUND INFORMATION  
There are multiple, non -invasive fat reduction procedures currently available for non-surgical body -
contouring.  Tech nologies include cryolipolysis, radiofrequency, high frequency focused ultrasound, and 
photobiomodulation.  All modalities deliver some form of energy that creates changes in the adipocy tes.  
Studies show that these therapies are safe and effective.   
Many non-invasive laser technologies have been studied  with the efficacy of laser therapy purported to 
be related to the wavelength and the energy delivered.  Initial lasers studied include the neodymium-
doped yttrium aluminum garnet (Nd:YAG) laser delivering 1064nm and 1320nm wavelengths.  Diode 
lasers were introduced delivering energy at 980nm, 924nm, 975nm and 920nm wavelengths.  The quest for the most effective laser diode wavelength for l ipolysis with the least adverse effect  continues, most 
recently with the 1064nm wavelength.   
The 1064nm laser diode leads to the injury of the adipocytes through direct heating of the tissue.  The 
energy delivered creates movement within the molecules of the exposed tissue, which then generates 
heat.  A controlled temperature of 42 -47 °C must be maintained at the site of adipocytes.  At this 

1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 2 of 26 
 temperature, the cell membranes of the adipocytes lose their structural integrity leading to cell death.   
Upon cell injury and death , the body naturally eliminates the contents of the adipocytes  with results at 6 
weeks but optimally at 12 weeks .  The 1064nm wavelength has a particular affinity for adipocytes with 
low absorption within the dermis.  In addition, melanin is minimally targeted so the device can be used 
in all skin types.  (Schilling L et al)  
RF energy heats the tissue and subcutaneous fat to trigger collagen remodeling and a reduction in 
subcutaneous fat.  The body’s response to RF creates a smoother appearance to the skin and reduced circumference.  Pulsed electromagnetic fields increase the vascularity of the skin and creates new 
pathways for the blood to flow.  This increase in blood will provide more oxygen to the skin and bring 
more nutrients to the tissue.  Suction is applied to the surface of the skin tissue  during treatment, 
increasing efficacy of the entire therapy . 
This study will investigate whether the Venus Bliss ™ investigational device is safe and efficacious for fat 
reduction of the flanks  and abdomen .   
 
2.2 RATIONALE  
 The objective of this clinical study is to evaluate the safety and efficacy of the use of the  Venus Bliss ™ 
investigational medical  device for  non- invasive fat reduction of the abdomen and flanks . 
 The use of the Venus Bliss™ has been determined to present non -significant risk in accordance with 21 
CFR 812.3 for the intended use in this study, because the device is not : 
• Intended as an implant;  
• purported or represented to be for use supporting or sustaining human life;  
• for use of substantial importance in diagnosing, curing, mitigating, or treating disease, or 
otherwise preventing impairment of human health; or  
• Otherwise present ing a potential for serious risk to the health, safety, or welfare of a subject.  
This study will be conducted in compliance with the protocol and according to Go od Clinical Practice 
(GCP) standards.  
2.3 POTENTIAL RISKS AND BENEFITS  
 
2.3.1  KNOWN PO TENTIAL RISKS  
Expected  adverse e vents  of the laser treatment procedure include transient tenderness, erythema, 
edema , and/or induration in the treated area  lasting from one to three weeks after the treatment .  In 
addi tion, other adverse events may include and include localized firmness, ecchymosis, skin burn, 
hyperpigmentation, hypopigmentation, blister and changes in skin laxity.  Rarely, skin contour 
irregularities, dimpling, asymmetry (uneven appearance due to uneven anatomy or uneven trea tment of 
the area), necrosis (tissue death), hardness and nodules occur.   Protective laser eyewear will be worn by 
the subject and operator providing the procedure.  
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 3 of 26 
 The device has a contact tissue  cooling system in place during the procedure to minimize thermal 
discomfort and prevent damage to the treatment area.   Expected a dverse events related to the contact 
cooling include tingling, itching, decreased sensation, numbness, erythema and tenderness.  
The potential risks of RF for adverse effects of the treatment procedure include but are not limited to 
blistering, burns, excessive edema or erythema, infection, scarring and post -inflammatory hyper or hypo 
pigmentation . 
 There are no known adverse effects with PEMF.  
Should the research site choose to capture one baseline and up to three additional follow up ultrasound images, th ere are minimal risks associated with the use of ultrasound for imaging.  The use of the 
ultrasound may cause redness of the skin.  Skin rashes rarely occur with the use of ultrasound gel.   
Risks will be mitigated by conducting this protocol with an investigator experienced in the therapeutic 
area of the clinical investigation.  The investigator will be trained by the sponsor on the use of the device.  The device design incorporates safety mechanisms which minimize risks.  Patients will also  be 
rigorously screened prior to their enrollment and rigorously followed over the course of the study.  
 
2.3.2  KNOWN POTE
 NTIAL BENEFITS  
If the subject agrees to participate in this study, he/ she will be contributing to the understanding of the 
safety and  efficacy of the use of this investigational device for fat reduction  of the abdomen and flanks .  
This understanding may lead to optimization of the treatment with th is device.  In addition , the subject 
may benefit from reduction in unwanted adipocytes . 
3 OBJECTIVES AND  PURPOSE  
The objective of this clinical study is to assess the safety and efficacy of using a 1064 nm diode laser , 
vacuum assisted RF and PEMF  for non -invasive fat reduction of the abdomen and flanks . 
Primary objectives  
• To determine propor tion of an independent, blinded reviewer,  who correctly identifies pre-
treatment baseline images and images taken at 16 and 24 weeks  post -treatment  
Secondary objectives  
• To assess subject satisfaction with treatment at 16 and 24 weeks  using the 5 -Point L ikert Subject 
Satisfaction Scale  
Safety 
• Subject’s assessment of dis comfort and pain  post -treatment as measured by the Wong -Baker 
Faces Pain rating scale. 
• Subjects experiencing a treatment-related adverse event ( AE). 
 
4 STUDY DESIGN AND ENDPOINTS 
 
4.1 DESCRIPTION OF THE STUDY DESIGN  
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 4 of 26 
 This is an open -label, baseline -controlled, evaluator -blind , mult i-center study evaluating treatments with 
a 1064 nm diode laser , vac uum assisted RF and PEMF for non -invasive fat reduction of the abdomen and 
flanks .   
4.2.1 PRIMARY ENDPOINT S 
• Photographic evaluation by  an independent, blinded reviewer with correct identification of pre -
treatment baseline images when compared to post -treatment images taken at  16 and 24 weeks   
 
4.2.2 SECONDARY ENDPOINTS  
• To assess subject satisfaction with treatment at 16 and 24 weeks using the 5 -Point Likert Subject 
Satisfaction Scale  
 
Safety Endpoints:  
• Report s ubject’s assessment of discomfort and pain as measured by  the Wong -Baker Faces Pain 
rating scale . 
• Report s ubject s experiencing a treatment-related adverse event (AE). 
 
5 STUDY ENROLLMENT AND WITHDRAWAL  
 
5.1 PARTICIPANT  INCLUSION CRITERIA  
1. Able to read, understand and  voluntarily provide written informed consent . 
2. Healthy male or female, ≥ 18 years of age  seeking treatment for unwanted  fat in the flanks . 
3. BMI score is less than 35.  
4. Agree to not making any major changes in their diet or lifestyle during the course of the stud y. 
5. Able and willing to comply with the treatment/follow-up schedule and requirements. 
6. Women of child-bearing age are required to be using a reliable method of birth control at least 3 
months prior to study enrollment and for the duration of the study, and have a negative Urine Pregnancy test at baseline. 
 
5.2 PARTICIPANT  EXCLUSION CRITERIA  
1. Pregnant  in the last 3 months , intending to become pregnant, postpartum or nursing in the last 
6 months.  
2. Any previous liposuction/lip o-sculpture or any type of surgical procedure in the treatment area 
in the past 12  months.  
3. History of immunosuppressi on/immune deficiency  disorders  (including AIDS and HIV infection ) 
or use of immunosuppressive medications, 6 months prior to and during the course of the study . 
4. History of hyperlipidemia, diabetes mellitus, hepatitis, blood coagulopathy or excessive bleeding. 
5. Use of antiplatelet medications (81  mg acetylsalicylic acid daily permitted), anticoagulants, 
thrombolytics or anti -inflammatory medications within 2 weeks of treatment.  
6. Having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions . 
7. Having a permanent implant in the treatment area such as metal plates or an inject ed chemical 
substance such as silicone  or parenteral gold therapy (gold sodium thiomalate) . 
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 5 of 26 
 8. Use of medications, herbs, food supplements, and vitamins known to induce photosensitivity to 
light exposure at the wavelength  used or history of photosensitivity disorder . 
9. Suffering from significant skin conditions in the treatment area or inflammatory skin conditions including but not limited to open lacerations, abrasions, herpes sores, cold sores, active infections. 
10. Tattoos  in the treatment area .  
11. Poor skin quality  (severe laxity) . 
12. Abdominal wall, muscular abnormality  or hernia on physical examination. 
13. Had an unstable weight within the past 6 months  
14. Use of retinoids such as oral isotretinoin ( Accutane™) within the past six months  or during 
course of the study . 
15. History of k eloid or hypertrophic scar formation  or poor wound healing in the treatment area. 
16. As per the inves tigator’s discretion, any physical or mental condition which may make it unsafe 
for the subject to participate.  
17. Unable or unlikely to refrain from  sun exposure,  artificial tanning, including the use of tanning 
booths, prior to (six weeks) and during the course of the evaluation.  
 
5.3 STRATEGIES FOR RECRUITMENT AND RETENTION  
Up to 200 subjec ts will be enrolled at up to 20  sites .  It is anticipated that it will take up to  twelve 
months  to complete the study.  Subjects requesting non-invasive lipolysis of the  abdomen and / or 
flanks  will be recruited primarily from the  investigator’s clinic.  Any advertising campaigns and materials 
will be reviewed and approved by an  institutional review  board  (IRB) before implementation.  Due to the 
duration of the study, subjects will be contacted by the investigative site on a regular basis in order to enhance retention . 
5.4 PARTICIPANT  WITHDRAWAL OR TERMINATION  
 
5.4.1 REASONS FOR WITHDRAWAL  OR TE RMINATION  
Subject s are free to withdraw from participation in the study without prejudice at any time upon 
request.   In the event that a subject drops out of the study or is withdrawn from the study, the End of 
Study/Early Discontinuation  CRF form should be completed. On the withdrawal page, the Investigator 
should record the date of the withdrawal and the reason for withdrawal. 
Reasonable effort should be made to contact any subject lost to follow up during the course of the study 
in order to complete assessments and retrieve any outstanding data.  The records of subjects who 
terminate prior to completing the study will be retained and the reason for termination will be documented.  
An investigator may terminate participation in the study if:  
• Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs such that continued participation in the study would not be in the best interest of the subject.  
• The subject  meets an exclusion criterion (either newly developed or not previously recognized) 
that precludes further study participation.  
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 6 of 26 
 5.4.2 HANDLING OF PARTICIPANT  WITHDRAWALS OR TERMINATION  
Every effort will be made to continue follow -up of withdrawn or terminated subjects or subjects  who 
discontinue the intervention but remain in the study for follow -up, especially for safety and efficacy 
study endpoints.  Every effort will be made to conduct a final visit and undertake protocol -specified 
safety follow -up procedures to capture A es, serious adverse events (SAEs), an d unanticipated problems 
(Ups).  
5.5 PREMATURE TERMINATION OR SUSPENSION OF STUDY  
 
The sponsor may suspend or prematurely terminate this study at an individual investigation site or the 
entire study for significant and documented reasons.  
 A principal investigator (PI), IRB, or regulatory authority may suspend or prematurely terminate participation in the study at the investigation site for which they are responsible.  
 If suspicion of an unacceptable risk to subjects arises during the study, or when so instructed by the IRB or regulatory authorities, the sponsor shall suspend the clinical investigation while the risk is assessed.  The sponsor shall terminate the study if an unacceptable risk is confirmed.  
 The sponsor shall consider  terminating or suspending the participation of the investigation site or 
investigator in the study if monitoring or auditing identifies serious or repeated deviations on the part of an investigator.  
If suspension or premature termination occurs, the terminating party shall justify its decision in writing 
and promptly inform the other parties with whom they are in direct communication. The principal investigator and sponsor shall keep each other informed of any communication received from either the IRB or  the regulatory authority.  
 
If, for any reason, the sponsor suspends or prematurely terminates the study at the investigation site, the 
sponsor shall inform the responsible regulatory authority as appropriate and ensure that the IRB is notified, either by the principal investigator or by the sponsor.  If the suspension or premature termination 
was in the interest of safety, the sponsor shall inform all other principal investigators.  
If suspension or premature termination occurs,  
a) the sponsor shall remain responsible for providing resources to fulfil the obligations from the 
protocol and existing agreements for following up the subjects enrolled in the study, and  
b) the principal investigator or authorized designee shall promptly inform the enrolled sub jects at 
the investigation site, if appropriate  
 In case of early termination, final study activities according to the protocol, including the follow -up visits 
and procedures to assess the safety and efficacy of the device will be conducted, regardless of the sponsor ’s interest in the study.  Follow -up activities will be conducted so that device deficiencies can be 
identified, and appropriate safety measures can be implemented.  
 At the completion or termination of the study, the Investigator will return all  remaining clinical supplies 
to Sponsor along with a copy of the device supply and inventory records. 
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 7 of 26 
  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants (examples of findings that might trigger a safety review are the number of SAEs overall, the number of occurrences of a particular type of SAE, severe Ae s/reactions, or increased frequency of events – 
refer to section 8.5 STUDY HALTING RULE S). 
• Demonstration of performance that would warrant stopping  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination of futility  
Study may resume once concerns about safety, protocol compliance, data quality and the like as the case may be are addressed and satisfy the sponsor, IRB and/or regulatory authorities. 
 
6 STUDY DEVICE  
 
6.1 STUDY DEVICE  AND CONTROL DESCRIPTION  
 
 ACQUISITION  
The Venus Bliss ™ investigational device will be shipped to the investigative site directly from the 
sponsor.  Training on the use of the device will be provided by the sponsor.  The investigative site will 
not perform any treatments until all regulatory and IRB  approvals are in place and the site has received 
training for both devices and the study.  
6.1. 2 DEVICE SPECIFIC CONSIDERATIONS  
The Venus Bliss™ investigational device  is a 1064nm diode laser system  intended for non -invasive 
lipolysis of the abdomen and flanks  in individuals with a Body Mass Index (BMI) of 35 or less.  The device 
consists of a console , four laser  applicator s and a  belt that secures the laser applicators in place  securely 
to the subje ct’s selected treatment area .  Each applicator includes contact tissue cooling and has an 
active area of 60mm x 60mm .  
The clinician is able to control the settings from the graphical user interface (GUI) display on the main 
console. Treatment time is 25 minutes. The available settings for this applicator is: 
• Optical power up to 1. 4 W/cm2  at 1064nm  
The vac uum assisted RF and PEMF applicator delivers the treatment radiofrequency and puls ed 
electromagnetic field therapy energy to the patient’s skin.  
The clinician is able to control the settings from the user interface (LCD GUI) display on the main 
Bliss console. The duration of treatment will be ≈15 minutes for a single treatment.  
 
6.2 S TUDY DEVICE  ACCOUNTABILITY PROCEDURES  
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 8 of 26 
 The device and applicators will be shipped to the site by the sponsor.  Traceability shall be achieved 
during and after the clinical investigation by assignment of serial numbers to device and applicators and 
accounting for the device and applicators returned to the sponsor by each site.  
The device will be labeled as an inves tigational device and  will require protocol and device training from 
the sponsor.  
7 STUDY PROCEDURES AND SCHEDULE 
 
7.1 STUDY PROCEDURES/EVALUATIONS  
7.1.1  STUDY SPECIFIC PROCEDURES   
The following procedures and evaluations will be done as part of the study : 
Demographics  
Medical / surgical history  
Physical examination  (as per site’s standard of care ) 
Assessment of eligibility  
Urine pregnancy test for women of child bearing potential  (visit 1 only)   
Optional baseline ultrasound and up to three additional ultrasound images taken  
Study Treatment(s)  
Photographs  
Administration of  questionnaires/scales for patient -reported outcome s (visit 1 and visit 3 only)  
Adverse event recording  
Concomitant medications  
7.2 LABORATORY PROCEDURES/EVALUATIONS    
 
7.2.1  CLINICAL LABORATORY EVALUATIONS  
For women of child-bearing potential, urine pregnancy test to be performed according to local site 
standards within 24 hours of study intervention .  Results must be available prior to administration of the 
treatment.   
7.3 ST UDY SCHEDULE  
 7.3.1  SCREENING 
Screening Visit  
If the subject meets the preliminary study criteria the study doctor, and/or his /her  designee, will obtain 
an informed consent from the subject, clearly indicating his/ her understanding of the requirements and 
possible risks involved with study participation and other applicable treatment options.  Subject s will 
receive a unique identifying number that will be composed of a two-digit site number and a three digit 
subject number in sequence.  This unique identifier will be used throughout the entire study and will be 
entered in the subject’ s case report form ( CRF) and for each treatment.  
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 9 of 26 
 During screening  visit, the study investigator, and/or his/her  designee, will assess the subject for eligibility 
to participate in the clinical study using the inclusion/e xclusion criteria.  A urine sample for the pregnancy 
test will be obtained  for female subjects  of chi ld-bearing potential .  During screening, the study doctor 
will review the subject ’s medical/surgical history and  examine the target  treatment area s to ensure they 
meet the study criteria.   
 
Subjects will be instructed to avoid sun exposure of the target treatment areas for at least six weeks before 
treatment and to use broad spectrum sunscreen of no less than 30 SPF daily.  In addition, tanning is to be 
strictly avoided.   
The investigator wi ll ask women of child -bearing potential for the date of their last period.  The 
investigator shall inquire about the form of contraceptive they use to confirm they meet the inclusion criteria. 
The subject will complete screening and the treatment will be s cheduled.  Treatment may be performed 
on the day . 
 
7.3.2  ENROLLMENT/BASELINE 
Enrollment/Baseline /Treatment  Visit (Visit 1 – Day 0) 
Pre-Treatment  
The investigator will confirm that the subject continues to meet the inclusion and none of the exclusion 
criteria.  Adverse events  and any changes to concomitant medications will be recorded.    
 The location and size  of the treatment area will be left to the principal investigator’s judgement based 
on his /her  assessment of individual subject requirements for treatment.  The defined  abdomen and or 
the flank  treatment area will be marked with a white laser pencil using a treatment template  as per the 
sponsor’s instructions.  Photographs of the marked treatment area . 
Treatment  
Protective eye goggles will be worn by both the patient and site staff performing the treatment for the 
duration of the treatment session.  
Based on the mild nature of treatment, anesthesia is not required. T he treatment procedure should 
include positioning of the patient in a manner that enables access to the target treatment  anatomical 
site.   
The belt will be positioned on the subject as per the marked treatment template.  Laser  applicators will 
be secured in place by the belt with  the area s treated for up to 25 minutes .  The laser energy will be 
delivered to the area while cooling is administered to the skin surface to increase subject comfort.   
Treatment will continue until the total treatment area has been treated.   
The assessment of disc omfort/pain during the treatment procedure will be assessed using the Wong -
Baker Faces Pain rating scale with treatment parameters adjusted accord ing to patient’s comfort level. 
Post Treatment  
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 10 of 26 
 Assessment  
The assessment of discomfort/pain based at  the subje ct’s completion of the Wong-Baker Faces Pain 
rating scale  should also be documented immediately after treatment.  
The normal response to this treatment is transient tenderness, edema and/ or induration in the treated 
area which should resolve within one to two weeks.  If any other side effects occur  or persist for longer 
than expected , they must be recorded  in the adverse event (AE) section of the case report form (CRF).   
For post -treatment cooling and/or discomfort , cold packs can be a pplied to t reatment  area if needed 
with a cetaminophen  at recommended doses  used to alleviate pain  as needed . 
During the day following treatment, care should be taken to prevent any mechanical or thermal damage 
to the treated sites:  avoid hot baths, massag e, contact sports, swimming, etc.  The treated areas should 
be kept clean to avoid contamination or infection.  The subject should be reminded to not make any 
major changes in their diet or lifestyle during the course of the study.  
Subjects will be discha rged from the clinic and will be schedul ed to return for the subsequent 
treatments at 8 and 16 weeks later . 
Optional vaccum assisted RF and PEMF treatments may be administered as per the discression of the physician (PI).  A 15 minute period should lapse between the diode therapy and the RF therapy.  
Treatment procedure should include positioning of the patient in a manner that enables access to the treated anatomical site. A layer of Glide™ is applied to the treatment area  – the entire waist using an 8 
½ x 11 sheet of paper as a guide.  This area is to be drawn out using an eyeliner or skin pen on both sides 
of the umbilicus.  
Select the RF/PEMF  applicator using the GUI and ATC.  The settings should populate to 75 % RF output 
for the oute r electrodes, 50% for the inner electrode  9only the 75% diplsays) , Varipulse 2 , time ≈15  
minutes and 0 interval time.  Set the target temperature to 42 -45 degrees C.  Press the start button to 
begin treatment. The aim is to heat the skin’s surface to a minimum of 42°C and a maximum of 45°C. Always try to treat at the highest temperature the subject can tolerate comfortably for optimal clinical results. Tissue temperature reading will be displayed on the screen .  
Treat half the abdomen at time with slow steady movements never pausing.  Applicator movements should be performed in random patterns of “8’s”, circles, elliptical, or zigzags covering the entire area.  At one minute the temperature should be approximately 42 °C or higher.  Once the temperature reaches 
42°C or higher, treat the other side of the abdomen as described above for one minute or until the 
temperature reaches 42 °C or higher. Once both sides have been treated for the initial minute, treat the 
entire abdomen in a random pattern assessing the pa tients comfort verbally.  If the patient is 
uncomfortable, speed up movements.  Slowing down movements increases the temperature in the skin. 
Note the final energy percentage at the end of treatment and the time spent treating the area at the final energy percentage.   
During the procedure, ensure that the electrodes of the applicator are gently pressed on the skin, 
making sure all electrodes are in contact with the skin at all times. In order to avoid overheating and to enhance the tolerance of the procedure, the applicator should be in constant motion.  If the measured 
skin surface temperature (when measured by an external  digital thermometer) at endpoint is less than 
42°C on the body, treatment is not optimal  and the desired results will not be accomplished.  Achieved 
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 11 of 26 
 skin temperature depends on applicator movement speed and energy level. The lower the energy the 
slower the movement should be and vi ce-versa. In the event that a subject experiences discomfort o r 
show signs of pain during the treatment, either decrease the energy %, or apply more Glide ™, or 
perform bigger and quicker movements or stop the treatment. The built -in ther mal sensor is being used 
only to verify that the recommended temperature (endpoin t) of the treated area is being achieved and 
maintained. In the event that a client suddenly does not feel good or in a distress, the Emergency Button 
MUST be pressed by the client or the operator.  By pressing the Emergency Button , the power supply 
will be switched off immediately.  
The Varipulse should be left at  the default of 2  for best clinical outcomes but can be reduced  or 
increased for a different feeling to the subject and for comfort, depending on the subject’ s skin type, to 
ensure that the applicator can move in a comfortable fashion on the skin.  It should never feel like the 
skin is being dr agged or pull ed  
During treatment, subject reaction must be monitored and if the subject report s an intolerable level of 
pain, treatment shall be ceased immed iately.  
The normal response to these treatments is transient erythema and edema  and the sensation of heat . 
These will not be considered as adverse events unless they are severe enough to stop treatment or warrant intervention or if the principal investiga tor determines they are adverse events.  If any  other  
adverse  effects occur, as indicated in the protocol, they will be recorded.  
 
7.3.3  FOLLOW UP AND FINAL
  STUDY VISIT 
Visit 24 (± 7 days)  
Subjects will return to the clinic 24 weeks  after the first treatment.  Adverse events  and any changes to 
concomitant medications will be recorded.   
If the site chose to capture ultrasound images, these would be captured during this visit.  
Photographs of the marked treatment area. Subjects will complete the satis faction survey and the treatment satisfaction form.   
The End of Study form will be completed and subjects will be discharged from the clinic and terminated 
from the study.    
The PI will record all reportable events with start dates occurring any time afte r informed consent is 
obtained until 7 (for non -serious Aes) or 30 days (for SAEs) after the last day of study participation.  
7.3. 4 EARLY TERMINATION VISIT  
Subjects who terminate the study early for whatever reason, will be asked to provide a reason for their early termination.  Adverse events and the reason for early termination will be recorded.  
7.3. 5 UNSCHEDULED  VI
 SIT 
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 12 of 26 
 If an unscheduled visit occurs, the reason for the unscheduled visit will be documented.  If the 
unscheduled visit is the result of an a dverse event, the event will be recorded on the adverse event CRF.  
 
7.4 CONCOMITANT MEDICATIONS, TREATMENTS, AND PROCEDURES  
All concomitant prescription medications taken during study participation will be recorded on the case 
report forms (CRFs).  For this protocol, a prescription medication is defined as a medication that can be 
prescribed only by a properly authorized/licens ed clinician.  Other medications to be reported in the CRF 
are concomitant over -the-counter medications and non -prescription medications. 
7.5 PROHIBITED MEDICATIONS, TREATMENTS, AND PROCEDURES  
The use of immunosuppressive medications , antiplatelet medicat ions, thrombolytics, anti -inflammatory 
medicatons and anticoagulant  medications is to be avoided.  Herbal supplements, perfumes , cosmetics 
and/or medications that may affect sensitivity to light  are prohibited.  The use of Accutane™ 
(Isotretin oin) within the past six months is also strictly prohibited.  
7.6 RESCUE MEDICATIONS, TREATMENTS, AND PROCEDURES  
In the event that the subject experiences pain, the principal investigator may prescribe any analgesic deemed appropriate to the level of pain .  If a subject experiences any first, second or third degree burn 
or pain beyond narcotics, then the following procedure will be implemented:  
Immediate triage and treatment of the patient shall be determined by the treating physician and based upon severity and type of burn identified.  
The event will be reported to the study Director within 24 hours of occurrence.  If the event meets the 
criteria of a SAE, then it must be reported on the SAE form.  
A copy of the patient chart and treatment parameters are to  be forwarded to the study Director within 
24 hours.   
The study Director will be responsible for issuing a written report to the company and the IRB  Chairman 
no later than 7 days from the incident.  
Long term follow up and care shall continue at the discr etion of the treating physician.  
All patients experiencing a complication of the device will be followed a minimum of 2 years following the initial injury.  Longer care and observation will be at the discretion of the treating physician.   
All minor compl ications such as appearance or altered sensation, except for pain, can be reported within 
30 days of patient complaint.  Both chart and treatment parameters are to be provided to the study Director and shared with the company and IRB  chairman.  
8 ASSESSMENT OF SAFETY  
 
8.1 SPECIFICATION OF SAFETY PARAMETERS  
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 13 of 26 
 In addition to spontaneous reports of adverse events, subjects will complete a Wong Baker  
discomfort/ pain visual pain scale and the principal investigator will examine the treated area and report  
immediate response. 
8.1.1  DEFINITION OF ADVERSE EVENTS  (A E) 
Adverse event means any untoward medical occurrence associated with the use of an intervention in 
humans, whether or not considered intervention -related (21 CFR 312.32 (a)).  
8.1.2  DEFINITION OF SERIOUS ADVERSE EVENTS  (SA E) 
NOTE: The term serious is not synonymous with severity, which may be used to describe the intensity of an event experienced by the subject). An AE that does not meet any of the below criteria will be classified as non -serious. 
A serious AE is any event that:  
• Results in, or contributes to a death;  
• Is immediately life  threatening (injury or illness); 
• Results in hospitalization, or prolongs an existing hospitalization;  
• Results in permanent impairment of body structure or function, or in persistent or significant disability/incapacity;  
• Results in an injury that requires medical intervention to prevent permanent impairment of body structure or function;  
• Is a device malfunction or deterioration in the characteristics and/or performance of the device 
that results in death or serious deterioration in health; 
• Is a device malfunction or deterioration in the characteristics and/or performance of the device 
that, if it were to occur again, could result in death or serious deterioration in health;  
• Results in a congenital anomaly or birth defect.  
• Is any medically significant injury, event or experience that requires medical/surgical intervention to prevent one of the outcomes listed above; 
• Results in end  organ toxicity, includin g hematological, renal, cardiovascular, hepatic, 
gastrointestinal, and central nervous system events;  
8.1.3  DEFINITION OF UNANTICIPATED PROBLEMS  (UP
 ) 
This definition  includes an unanticipated adverse device effect, any serious adverse effect on health or 
safety or any life -threatening problem or death caused by, or associated with, a device, if that effect, 
problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects (21 CFR 812.3(s )). 
8.2 CLASSIFICATION OF AN ADVERSE EVENT  
 
8.2.1  SEVERITY OF EVENT  
For Ae s not included in the protocol defined grading system, the following guidelines will be used to 
describe severity.  
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 14 of 26 
 • Mild  – Events require minimal or no treatment and do not interfere with the participant’s daily 
activities. 
• Moderate  – Events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with func tioning.  
• Severe – Events interrupt a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life-threatening or 
incapacitating.  
8.2.2  RELATIONSHIP TO STUDY AGENT  
The clinician’s as sessment of an AE ’s relationship to the study agent is part of the documentation 
process, but it is not a factor in determining what is or is not reported in the study. If there is any doubt as to whether a clinical observation is an AE, the event should b e reported. All Aes must have their 
relationship to study agent assessed. In a clinical trial, the study product must always be suspect. To help assess, the following guidelines are used.  
• Related  – The AE is known to occur with the study agent, there is a reasonable possibility that 
the study agent caused the AE, or there is a temporal relationship between the study agent and event. Reasonable possibility means that there is evidence to suggest a causal relationship 
between the study agent and the AE.  
• Not Related – There is not a reasonable possibility that the administration of the study agent 
caused the event, there is no temporal relationship between the study agent and event onset, 
or an alternate etiology has been established.  
8.2.3  EXPECTEDNESS  
Expected adverse reactions are Ae s that are common and known to occur for the study agent being 
studied.  Expected  adverse e vents  of the treatment include transient tenderness, erythema, edema , 
and/ or induration in the treated area  lasting from one to three  weeks after the treatment.   
The device has a contact tissue cooling system in place during the procedure to minimize thermal discomfort and prevent damage to the treatment area.   Expected adverse events related to the contact cooling include tingling, itching, decreased sensation, numbness, erythema and tenderness.   
An AE or suspected adverse reaction is considered “ unexpected ” if it is not known to occur for the study 
treatment being studied and at the specificity or severity that has been observed. 
8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP 
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and interviews of a study participant presenting for medical care, or upon review by a study moni tor. All Ae s 
including local and systemic reactions not meeting the criteria for SAEs will be captured on the appropriate CRF. Information to be collected includes event description, time of onset, clinician’s 
assessment of severity, relationship to study product (assessed only by those with the training and authority to make a diagnosis), and time of resolution/stabilization of the event. All Aes occurring while on study must be documented appropriately regardless of relationship. All A es will be followed to 
adequate resolution.  
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 15 of 26 
 Any medical condition that is present at the time that the participant is screened will be consider ed as 
baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any 
time during the study, it will be recorded as an AE. U ps will be recorded in the data collection system 
throughout the study.  
Changes in the severit y of an AE will be documented to allow an assessment of the duration of the event 
at each level of severity to be performed. Aes characterized as intermittent require documentation of 
onset and duration of each episode.  
The PI will record all reportable ev ents with start dates occurring any time after informed consent is 
obtained until 7 (for non -serious Aes) or 30 days (for SAEs) after the last day of study participation. At 
each study visit, the investigator will inquire about the occurrence of AE/SAEs si nce the last visit. Events 
will be followed for outcome information until resolution or stabilization.  
8.4 REPORTING PROCEDURES  
 
8.4.1  ADVERSE EVENT REPORTING  
All Aes will be recorded on the appropriate CRF and will include information about the start and stop 
dates, severity and relatedness.  There should be an attempt to report a “diagnosis” rather than the 
individual signs, symptoms and abnormal laboratory values associated with the diagnosis. However, a 
diagnosis should be reported only if, in the Investigator’s judgment, it is relatively certain (i.e., definite or possible). Otherwise individual signs, symptoms and abnormal laboratory values should be reported as distinct adverse events.  
8.4.2  SERIOUS ADVERSE EVENT REPORTING  
All serious AE, whether or not deemed expected or device related, must be reported to the  sponsor’s 
clinical research department immediately or within 24 hours by telephone (see contact details below). 
 
 
 
A writt
en report prepared by the Principal Investigator must follow within seven working days to the 
clinical monitor and should include a full description of the event and sequence.  
The study investigator shall complete a Serious Adverse Event / Serious Adverse Device Effect Form and 
submit to the study sponsor and to the reviewing IRB as soon as possible, but in no event later than 10 
working days after the investigator first learns of the effect. The study sponsor contact information is provided in Section 1, Key Roles. The study sponsor is responsible for conducting an evaluation of an unanticipated adverse device effect and shall report the results of such evaluation to Health Canada, the 
FDA or local regulatory agency and to all reviewing IRB s and participating investi gators within 10 
working days after the sponsor first receives notice of the effect. Thereafter the sponsor shall submit such additional reports concerning the effect as Health Canada, the FDA or local regulatory agency requests.  
8.4.3  UNANTICIPATED PROBLE M R E
 PORTING  

1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 16 of 26 
 Incidents or events that meet the criteria for U ps require the creation and completion of an UP report 
form. It is the site investigator’s responsibility to report U ps to their IRB  and to the study sponsor. The 
UP report will include the follo wing information:  
Protocol identifying information: protocol title and number, PI’s name, and the IRB  project number ; 
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome 
represents an UP;  
• A description of any changes to the protocol or other corrective actions that have been taken or 
are proposed in response to the UP.  
An investigator shall submit to the sponsor and to the reviewing IRB  a report of any unanticipated 
adverse device effect occurring during an investigation as soon as possible, but in no event later than 10 
working days after the investigator first learns of the effect  (21 CFR 812.150(a)(1)), A sponsor who 
conducts an evaluation of an unanticipated adverse device effect under 812.46(b) shall report the 
results of such evaluation to Health Canada, the FDA or local regulatory agency and to all reviewing IRB’s 
and participating investigators within 10 working days after the sponsor first receives notice of the 
effect. Thereafter the sponsor shall submit such additional reports concerning the effect as FDA (21 CFR 812.150(b)(1))  or local regulatory agency requests.  
8.4. 4 REPOR
 TING OF PREGNANCY  
If a subject becomes pregnant during the course of the study, the subject will be terminated from the 
study. The pregnancy will be immediately reported to the sponsor on the Notification of Subject or 
Partner Pregnancy form and to the  IRB using the same reporting timelines as a SAE. The investigator will 
follow the pregnancy until completion and will report the outcome of the pregnancy to the sponsor on the Notification of Subject or Partner Pregnancy Outcome form and the IRB  within 10 business days. 
8.5 STUDY HALTING RULES  
The study may be halted at any time by the sponsor, the IRB , Health Canada, the FDA or local regulatory 
agencies due to safety concerns.  Examples of findings that might trigger a safety review are the number 
of SAEs overall, the number of occurrences of a particular type of SAE, severe A es/reactions, or 
increased frequency of events.  If the study is halted, the sponsor will immediately noti fy all 
investigational sites, the IRB (s), Health Canada,  the FDA  or local regulatory agenc ies. 
8.6 SAFETY OVERSIGHT  
Independent oversight is an important component to ensure human subjects ’ protection.  Safety 
oversight will be under the direction of the sponsor and a medical monitor.  
9 CL INICAL MONI TORING 
Clinical site monitoring is conducted to ensure that the rights and well-being of human subjects are protected, that the reported trial data are accurate, complete, and verifiable, and that the conduct of the trial is in compliance with the currently approved protocol/amendment(s), with GCP, and with applicable regulatory requirement(s).  
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 17 of 26 
 • Monitoring for this study will be performed by the sponsor or designate. 
• On-site  monitoring will occur within 4 weeks of first enrolled subject  (s) and will occur as often 
as required per site. 
• The Study Director or designate will be provided copies of monitoring reports within 15 business  
days of visit.  
10 STATISTICAL CONSIDERATIONS   
 
10.1 STATISTICAL AND ANALYTICAL PLANS 
The Statistical and Analytical Plans (SAP) may be revised during the study to accommodate Clinical Trial 
Protocol Amendments and to make changes to adapt to unexpected issues in study execution and data 
that affect planned analyses.  If revised, a formal SAP will be completed and issued prior  to database 
lock and unblinding of the study data . 
10.2 ANALYSIS DATASETS  
The null and alternative hypotheses for the study’s primary, key secondary and safety endpoints are;  
• Primary Efficacy  Endpoint s: Statistical hypothesis will not be applied in the analysis of the study’s 
primary endpoint  
 
• Secondary Efficacy Endpoint(s):  
 
o Null Hypothesis (H o: µd = µpost – µpre = 0) – There is no satisfaction with the treatment at 
twelve weeks  using the 5 -Point Likert Subject Satisfaction Scale  as assessed by the 
subjects.  
 
Alternative Hypothesis (H a: µd = µpost – µpre ≠ 0) – There is satisfaction with the treatment 
at twelve weeks  using the 5 -Point Likert Subject Satisfaction Scale as assessed by the 
subjects.  
• Safety Endpoint: Statistical hypothesis will not be used in the analysis of the study’s safety 
endpoint.  
10.3 DESCRIPTION OF STATISTICAL METHODS  
The Intention -to-Treat Analys is Dataset will be used; efficacy  and safety analyses will be carried out on all 
subjects who underwent  Venus Bliss™ treatment. 
10.4.1  GENERAL APPROACH  
This is an open -label, baseline -controlled, evaluator -blind multi -center study evaluating treatment with  
a 1064 nm diode laser , vaccum assisted radio frequency and pulsed electromagnetic fields for non-
invasive fat reduction of the abdomen and flanks .   
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 18 of 26 
 All summary tables for quantitative parameters will display mean, standard deviation, median, range 
(minimum and maximum), percentages as well as number of missing data (if relevant).  All summary 
tables for qualitative parameters will display counts, perc entages and number of missing data if 
relevant. Baseline data are defined as the last photograph and measurement performed before the first treatment on Visit 1.  
All statistical tests will be two -sided, where applicable. The level of statistical significa nce for 
effectiveness analyses is 5% (α = 0.05) for all tests of differences. Where appropriate, t -test and/or two -
proportion z- test will be used to compare outcome at twelve weeks  post -treatment as compared to 
baseline . This test will enable us to accept or reject the null hypotheses. Rejection of null hypotheses will 
establish that:  
• The two -sided 95% confidence interval for the difference between the means excludes zero.  
• The two means are statistically significantly different at the 5% level ( P < 0.05) two -sided.  
Upon rejection of null hypotheses, further statistical test tools such as Confidence Interval, and/or One -
way ANOVA and/or descriptive statistical tools may be used to determine the performance of the treatment.  
In order to accommodate imb alances of some baseline of scores or measurements, covariate adjustment 
analysis may be performed in SAP to estimate adjusted treatment effects for the primary endpoint analysis.  
The assumption for the statistical test is that variables are normally distributed within study  group and 
the variation of scores  or measurements at twelve weeks  post -treatment as compared to baseline is not 
reliably different . 
The safety analysis will be done by analyzing spontaneous reports of adverse events (AE), subjects’ 
completed Wong Baker  visual pain scale  and immediate response reports by the principal investigator 
from his/her observation/examination of the treated area.  Appropriate Medical Dicti onary for 
Regulatory Activities (MedDRA) code will be used to describe all spontaneously reported or other study related adverse events.  
10.4.2 ANALYSIS OF THE PRIMARY ENDPOINTS  
The following will be consider for the analysis primary endpoints: 
The results  of a Blinded Reviewer’s evaluation of photographs taken at 16 and 24 weeks  compared to 
baseline will be analyzed and the results will be reported as a % of the correctly identified post treatment 
photographs chosen per Blinded Reviewer. An average of the % of the correctly identified post treatment 
photographs chosen by Blinded Reviewer will be calculated and used to determine   
 Bar, pie charts or grap hs indicating percentages of the correctly identified post treatment photographs 
chosen by  Blinded Reviewer  may also be used to  analyse efficacy.  
The efficacy endpoint to treatment will be defined by a n average of the 65% of the correctly identified 
post treatment photographs chosen by Blinded Reviewer This will be used to determine if the study meet s 
the primary endpoint  expectation.  
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 19 of 26 
 The % of the correctly identified post treatment photographs chosen by  Blinded Reviewer of all subjects 
who received at least one treatment of Venus Blis s™  and for whom at least one valid post -baseline 
assessment were obtained will be analysed for these primary  endpoints. Mutiple imputation  method or 
modelling of available data may be used for missing data as appropriate.  
10.4.3  ANALYSIS OF THE SECONDARY ENDPOINTS  
For the analysis of subjects’ assessment of satisfaction with the treatment secondary endpoints  the 
following analysis will be considered:  
Bar charts, pie chart, graphs or any other descriptive statistical displays indicating scores, percentages  
and/ or proportions of subjects assessment of satisfaction  at 16 and 24 weeks  post -treatment will be used  
where applicable to analyse efficacy.  
 
All statistical tests that will be two -sided. The level of statistical significance for effectiveness analyses is 
5% (α = 0.05) for all tests of differences. Where appropriate, two-proportion z -test will be used to compare 
the subjects’ assessment of satisfaction  at twelve weeks  post -treatment.   Analysis of Covariance 
(ANCOVA) may also be used where appropriate.  
Mutiple imputation  method or modelling of available data may be used for missing data as appropriate.  
10.4.5  SAFETY  AN ALYSIS  
The safety analysis will be done by analyzing spontaneous reports of adverse events  (AE), subjects ’ 
complete d 10 point Wong Baker  visual pain scale and a response questionnaire. Appropriate Medical 
Dictionary for Regulatory Activities (MedDRA ) code will be used to describe al l spontaneous ly report ed or 
other study related adverse events . 
Summaries of spontaneous ly report ed or other study related  adverse events  will be presented as : 
o Number (%) of subjects with any AE,  
o Number (%) of subject s with any  serious adverse events (SAE), 
o Number (%) of subject s permanently wit hdrawn from treatment due to AE  
Summaries of analysis of immediate response reports by the principal investigator  examination will be 
displayed on a  bar or pie chart as;  
o the overall frequency of subject s with ea ch event (pain during treatment, hemorrhage, burn, 
erythema, edema, purpura)  
o Frequency of subject s with specific severity/ intensity for each event  using a 5 points scale: 
1=none; 2=trace; 3=moderate; 4=marked; 5=severe  
o The overall percentage  or proportion of subject observed with marked or severe intensity of any 
event will be calculated and compared to those with none, trace or moderate severity/intensity with the aid of a bar or pie chart.  
The following will be considered for the analysis of 10 Wong Baker  visual pain scores  safety data: 
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 20 of 26 
 A summary table of the 10 wong baker visual pain  scores  post treatment will be displayed as mean 
difference, standard deviation and standard error.  The Wong baker visual pain scale  is a 11-level (0 to 10) 
ordinal scal e tool for assessing pain.  
 
The overall percentage or proportion of subject that recorded  marked or severe post treatment 
discomfort/pain visual pain  scores  may  be calculated and compared to those with none, trace, low  or 
moderate discomfort/pain using  a bar or pie chart .  
10.4.6  ADHERENCE AND  R ETENTION ANALYSES  
Adherence to the protocol will be assessed  by calculating the number or (%) subjects’ data for each 
endpoint assessment that is not provided in subjects Case Report Forms. This will be further analyzed as per frequency of each endpoint data that is not available due to l oss to follow -up, discontin uation of the 
intervention or any other reason .
 
10.4.7  BASELINE DESCRIPTIVE STATISTICS  
Subjects baseline measurements and scores  of all applicable endpoints will be compared using 
descriptive statistics such as mean score, standard deviation, standard err or, range and graphical 
presentations.  
10.4.8  PLANNED INTERIM ANALYSES  
No interim analysis is planned.   
10.4.8 .1 SAF ETY REVIEW  
There will be no interim analysis during this study. However, t his study may be temporarily suspended or 
prematurely terminated if there is sufficient reasonable cause as per section 5.5 and 8.5.  
10.4.8 .2 EFFIC ACY REVIEW  
There will be no interim analysis during this study. However, this study may be temporarily suspended 
or prematurely terminated if there is sufficient reasonable cause  as per section 5.5 and 8.5.  
10.4.9  ADDITIONAL SUB -GROUP ANALYSES  
Not applicable.  Primary or secondary endpoint s may  be analyzed based on age, sex, race/ethnicity or 
other demographic characteristic(s) . 
10.4.10 TABULATION OF INDIVIDUAL RES PONSE DATA  
Individual participant data will be listed by measure and time point  as appendix to the study report . 
10.4.11 EXPLORATORY ANALYSES  
Not applicable.  
10.5  SAMPLE SIZE  
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 21 of 26 
  
10.6.1  ENROLLMENT/ RANDOMIZATION/ MASKING PROCEDURES  
At screening, once a subject has signed the informed consent, and inclusion/exclusion criteria has been 
met, a subject number will be assigned. Subjects will receive a unique identifying number that will be 
composed of a two -digit site number and a three digit subject number in sequence.  This unique 
identifier will be used throughout the entire study and will be entered in the subject ’s case report form 
(CRF) and for each treatment. Subjects are not randomized; this is an open -label, baseline-controlled, 
evaluator -blind multi -center study.  
 
10.6.2  EVALUATION OF SUCCESS OF BLINDING  
This is an open -label, baseline -controlled, evaluator -blind multi -center study; only the independent 
reviewers will be blinded.  
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  
Each participating site will maintain appropriate medical and research records for this trial, in compliance with ICH E6 , ISO 14155:2011, HIPAA  and regulatory and institutional requirements for the 
protection of confidentiality of participants.  Each site will permit authorized representatives of the 
study sponsor  and regulatory agencies to examine (and when permitted by applicable law, to copy) 
clinical records for the purposes of quality assurance reviews, audits, and evaluation of the stud y safety, 
progress, and data validity.  
Source data are all information, original records of clinical findings, observations, or other activities in a 
clinical trial necessary for the reconstruction and evaluation of the trial. Examples of these original documents and data records include, but are not limited to, hospital records, clinical and office charts, 
laboratory notes, memoranda, participants ’ memory aids or evaluation checklists, pharmacy dispensing 
records, recorded audio tapes of counseling sessio ns, recorded data from automated instruments, 
copies or transcriptions certified after verification as being accurate and complete, microfiches, 
photographic negatives, microfilm or magnetic media, x-rays, and participant files and records kept at the phar macy, at the laboratories, and medico -technical departments involved in the clinical trial.  
It is acceptable to use CRFs as source documents. The 5-point Likert Subject satisfaction Scale , treatment 
evaluation and visual pain scale  data for this study wil l be collected on the CRF.  The immediate 
response as assessed by the principal investigator will be collected on the CRF with the remainder of the 
data  collected from other sources.   It is no t acceptable for the CRF to  be the only record of a subject’s  
participation in the study. This is to ensure that anyone who would access the patient medical record has adequate knowledge that the patient is participating in a clinical trial.  
12 QUALITY ASSURANCE AND QUALITY CONTROL 
Prior to any independent use of the Venus Bliss™ investigational device, study personnel will receive 
proper training from the sponsor.  Site personnel will be trained on the use of the device prior to study 
initiation at the site.  Additional t raining requirements will be discussed during study initiation and will 
include site responsibilities, and study documentation.   In addition, the sponsor will provide protocol 
specific training for the site.  The site will document which individual has been assigned to a specific task 
and will ensure that appropriate training has occurred for that task.  
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 22 of 26 
 Regular monitoring and an independent audit, if conducted, must be performed according to ICH -GCP  
and ISO 14155:2011. See also Section 9, Clinical Monitoring . 
Quality control ( QC) procedures will be implemented beginning with the data entry system and data QC 
checks that will be run on the database will be generated. Any missing data or data anomalies will be 
communicated to the site(s) for clarification/resolut ion. 
Monitors will verify that the clinical trial is conducted and data are generated, documented (recorded), 
and reported in compliance with the protocol, GCP, and the applicable regulatory requirements.  
The investigational site will provide direct access  to all trial related sites, source data/documents, and 
reports for the purpose of monitoring and auditing by the sponsor, and inspection by local and regulatory authorities.  
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  
 
13.1 ETHICAL STANDARD  
The investigator will ensure that this study is conducted in full conformity with Regulations for the 
Protection of Human Subjects of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, and/or the ICH E6 , the Declaration of Helsinki, Council for Internatio nal Organizations of Medical Science 
(CIOMS), ISO 14155:2011, International Ethical Guidelines for Biomedical Research Involving Human 
Subjects (2002), or another country’s  ethical policy statement, whichever provides the m ost protection 
to human subjects.  
13.2 INSTITUTIONAL REVIEW BOARD  
The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the IRB for review and approval.  Approval of both the protocol and the consent form must 
be obtained before any participant is enrolled.  Any amendment to the protocol will require review and 
approval by the IRB  before the changes are implemented to the study.  All changes to the consent form 
will be IRB  approved; a determination will be made regarding whether previously consented participants 
need to be re -consented.  
13.3 INFORMED CONSENT PROCESS  
 
13.3.1  CONSENT/ASSENT AND OTHER INF ORMATIONAL DOCUMENTS PROVIDED TO 
PARTICIPANT S 
Informed consent is required for all subjects in a study.  In obtaining and documenting informed 
consent, the investigator should comply with applicable regulatory requirements and should adhere to 
45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, or equivalent local regulatory regulations or guidelines  
and/or ICH GCP.  Prior to the  ̭̼ͮbeginning of a trial, the investigator should have the IRB ’s written approval 
for the protocol and the written informed consent  forms(s) and any other written information to be 
provided to the participants.  Consent forms describing in detail the study agent, study procedures, and 
risks are given to the participant and written documentation of informed consent is required prior to  
starting intervention/administering study product.  
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 23 of 26 
 13.3.2  CONSENT PROCEDURES AND D OCUMENTATION 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the 
study and continues throughout the individual’s study p articipation.  Extensive discussion of risks and 
possible benefits of participation will be provided to the participants and their families.  Consent forms 
will be IRB -approved and the participant will be asked to read and review the document.  The 
investigator will explain the research study to the participant and answer any questions that may arise. All participants will receive a verbal explanation in terms suited to their comprehension of the purposes, procedures, and potential risks of the study and of  their rights as research participants.  Participants will 
have the opportunity to carefully review the written consent form and ask questions prior to signing. 
The participants should have the opportunity to discuss the study with their surrogates or thin k about it 
prior to agreeing to participate.  The participant will sign the informed consent document prior to any 
procedures being done specifically for the study.  The participants may withdraw consent at any time 
throughout the course of the trial.  A copy of the informed consent document will be given to the 
participants for their records.  The rights and welfare of the participants will be protected by 
emphasizing to them that the quality of their medical care will not be adversely affected if they dec line 
to participate in this study.  
13.4 PARTICIPANT  AND DATA CONFIDENTIALITY  
Participant confidentiality is strictly held in trust by the participating investigators, their staff, and the 
sponsor(s) and their agents.  This confidentiality is extended to cover testing of biological samples and 
genetic tests in addition to the clinical information relating to participants.  Therefore, the study 
protocol, documentation, data, and all other information generated will be held in strict confidence.  No 
information concerning the study or the data will be released to any unauthorized third  party without 
prior written approval of the sponsor.  
The study monitor, other authorized representatives of the sponsor, representatives of the IRB  or device 
company supplying study product may inspect all documents and records required to be maintained by the investigator, including but not limited to, medical records (office, clinic, or hospital) and pharmacy records for the participants in this study.  The clinical study site will permit access to such records. 
The study participant’s contact information will be securely stored at each clinical site for internal use during the study.  At the end of the study, all records will continue to be kept in a secure location for as 
long a period as dictated by the sponsor, local IRB  and any other  regulations.  
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted to and stored at the sponsor’s offic e.  This will not include the participant’s contact or 
identifying information.  Rather, individual participants and their research data will be identified by a 
unique study identification number.  The study data entry and study management systems used by 
clinical sites and by sponsor’s research staff will be secured and password protected.  At the end of the 
study, all study databases will be de -identified and archived by  the sponsor . 
13.4.1 RESEARCH USE O F 
 STORED HUMAN SAMPLES, SPECIMENS  OR DATA  
The inves tigator will store all data according to the local regulatory standards.  
14 DATA HANDLING AND RECORD KEEPING  
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 24 of 26 
  
14.1 DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site 
PI.  The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of 
the data reported.  
All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data.   Black ink is required to ensure clarity of reproduced copies.  When making changes or 
corrections, cross out the original entry with a single line, and initial and date the change. DO NOT ERASE, OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
Copies of the paper CRF will be provided for use as source documents and maintained for recording data 
for each participant enrolled in the study.  Data reported i n the CRF derived from source documents 
should be consistent with the source documents or the discrepancies should be explained and captured 
in a progress note and maintained in the participant’s official study record.   Self-reported subject data 
recorded on the non -carbon copy CRF page is permitted.  The original form will be collected by the 
sponsor and the copy will remain at the site.  
Clinical data (including Ae s, concomitant medications, and expected adverse reactions data) and clinical 
laboratory data from paper CRFs will be collected by the study sponsor and will be entered directly onto 
paper CRFs from the source documents.  
14.2 STUDY RECORDS RETENTION  
Study documents, including copies of the paper CRFs, signed informed consent forms, photographs, 
laboratory results, medical records , data clarification forms  and regulatory documents,  should be 
retained for a minimum of 2 years after the last approval of a marketing application in an ICH region and 
until there are no pending or contemplated marketing applications in an ICH region or until at least 2 
years have elapsed since the formal discontinuation of clinical development of the investigational product.  These documents should be retained for a longer period, however, if required by loc al 
regulations.   No records will be destroyed without the written consent of the sponsor, if applicable. It is 
the responsibility of the sponsor to inform the investigator when these documents no longer need to be retained. 
14.3 PROTOCOL DEVIATIONS  
A prot ocol deviation is any noncompliance with the clinical trial protocol or GCP requirements. The 
noncompliance may be either on the part of the participant, the investigator, or the study site staff. As a result of deviations, corrective actions are to be dev eloped by the site and implemented promptly.  
These practices are consistent with ISO 14155:2011 and ICH E6:  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.20 Noncompliance, sections 5.20.1, and 5.20.2.  
It is the responsibility of the site to use continuous vigilance to identify and report deviations within 10 working days of identification of the protocol deviation, or within 10  working days of the scheduled 
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 25 of 26 
 protocol -required activity. All deviations must be addressed in study source documents. Protocol 
deviations must be sent to the local IRB per their guidelines. The site PI/study staff is responsible for 
knowing and adhering to their IRB  requirements.  
14.4 PUBLICATION AND DATA SHARING POLICY  
The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a 
clinical trials registration policy as a condition for publication. The ICMJE defines a clinical trial as any research project  that prospectively assigns human subjects to intervention or concurrent comparison or 
control groups to study the cause-and -effect relationship between a medical intervention and a health 
outcome. Medical interventions include drugs, surgical procedures, devices, behavioral treatments, process -of-care changes, and the like. Health outcomes include any biomedical or health-related 
measures obtained in patients or participants and adverse events.  The ICMJE policy, and the Section 801 of the Food and Drug Ad ministration Amendments Act of 2007, requires that all clinical trials be 
registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by the National Library 
of Medicine. Other biomedical journals are considering adopting similar policies. The ICMJE does not 
review specific studies to determine whether registration is necessary; instead, the committee recommends that researchers who have questions about the need to register err on the side of registration or consult the editorial office of the journal in which they wish to publish.  
The sponsor or designated principal investigator  will register and report results of certain “applicable 
clinical trials ”: 
• Trials of Devices: Controlled trials with health outcomes of a product subject to  Health Canada 
or FDA regulation (other than small feasibility studies) and pediatric post market  surveillance 
studies.  
15 STUDY ADMINISTRATION  
 
15.1 STUDY LEADERSHIP  
The study will be administered by the sponsor.  
16 CONFLICT OF INTEREST POLICY  
The indepen dence of this study from any actual or perceived influence, such as by the device industry, is 
critical.  Therefore, any actual conflict of interest of persons who have a role in the design, conduct, 
analysis, publication, or any aspect of this trial will be disclosed and managed.  Furthermore, persons 
who have a perceived conflict of interest will be required to have s uch conflicts managed in a way that is 
appropriate to their participation in the trial.  The sponsor will ensure that all study group members 
disclose all conflicts of interest and will establish a mechanism for the management of all reported dualities of interest. 
17  LITERATURE REFERENCES  
1064 Diode Laser, vaccum assisted RF and PEMF for Non- invasive Fat Reduction of the Abdomen and Flanks  Version 5.0  
Protocol  #BL0319 29 October 2019 
Page 26 of 26 
 Alizadeh Z, Halabchi F, Mazaheri R, et al.  Review of the Mechanisms and Effects of Noninvasive Body 
Contouring Devices on Cellulite and Subcutaneous Fat.  Int J Endorcrinol Metab. 2016 Oct; 14(4): 
e36727. 
Auh SL, Iyeng ar S, Weil A, Bolotin D et al.  Quantification of Noninvasive Fat Reduction:   A Systematic 
Review.  Laser in Surg Med.  2018 50:  96-110.  
Bass LS, Doherty ST. Safety and Efficacy of a noninvasive 1064nm Diode Laser for Fat Reduction of the 
Abdomen .  J Drugs Dermatol. 2018 17(1):  106-112 
Chilukuri S, Mueller G.  “Hands Free” Noninvasive Body contouring Devices:  Review of Effectiveness and Patient Satisfaction.  J Drugs Derm atol. 2016 15(11):  1402-1406.  
Decorato JW, Chen B, Sierra R.  Subcutaneous Adipose Tissue Response to a Non -Invasive Hyperthermic 
Treatment using a 1064nm Laser.  Lasers in Surg Med.  2017 49(5):  480-489.  
Godwin M, Pike A, Bethune C et al. Concurrent and Convergent Validity of the Simple Lifestyle Indicator Questionnaire.  ISRN Family Medicine Volume 2013, Article ID 529645, 6 pages.  
Katz B, Doherty S.  Safety and Efficacy of a Noninvasive 1064nm Diode Laser for Fat Reduction of the Flanks.  Dermatol Surg. 2018 44(3):  388-396. 
McBean JC, Katz BE.  Laser Lipolysis:  An Update.  J Clin Aesthetic Derm.  2011 4(7): 25 -34. 
Schilling L, Saedi N, Weiss R. 1064 nm Diode Hyperthermic Laser Lipolysis: The Latest in Non-Invasive 
Body Contouring. J Drugs Dermatol. 2017 Jan 1;16(1):48-52. 
Amir  R. Clinical Evaluation on the Efficacy and Safety of the VelaShape III Device for Abdominal 
Circumferential Reduction Treatments. Syneron 2013 .
 
APPENDIX  
 
Version  Date  Significant Revisions  
V2 July 2, 2019  Spelling errors for the word vacuum corrected, header 
corrected from 1064nm to 1064 nm 
V3 July 29, 2019  Added “and abdomen” to page 3 and 4 as a correction a sit 
stated flanks.  
V4 August 21, 2019  Updated date, V4, post market product not pre, added a 
follow up to subject visits, clarified three treatments and 
updated timeline, added a photographic evaluation to visit 8, 
16, 24  and updated monitoring timeline  
V5 October 29,2019  Updated version numb er, date, contact info, 1060nm change 
to reflect tested wavelength of 1064nm ±10nm, added optional ultrasound images (baseline and up to three 
additional)  
 